-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Industry News & Regulatory Approvals
-
In Brief for June 25, 2025
The US FDA recently granted approval to taletrectinib for ROS1-positive NSCLC and accepted a priority review for lurbinectedin plus atezolizumab for ES-SCLC in the first-line setting.
-
In Brief for June 11, 2025
VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.
-
Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs
According to recent phase II data, the experimental treatment demonstrated a median overall survival of 24.5 months.
-
In Brief for May 28, 2025
The US FDA grants accelerated approval to telisotuzumab vedotin-tllv for advanced NSCLC with high c-Met overexpression.
-
In Brief for May 14, 2025
Pembrolizumab-chemotherapy combo receives Canadian approval for first-line treatment of malignant pleural mesothelioma.
-
In Brief for April 23, 2025
The US FDA announces the approval of two IND applications, as well as for bevacizumab-nwgd.
-
Foritinib Gains Momentum in China for ALK-positive NSCLC
China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial.
-
Zipalertinib Meets Primary Endpoint in Phase 2b Trial
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations.
-
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent.
-
US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.
View ILCN Archives
Provider Resources
Popular Articles